Boston is one of the most active M&A markets in the US, with strong deal flow across technology, life sciences, healthcare, and business services. This list covers 10 active M&A advisors in 2026 - deal sizes, sector focus, and verified recent transactions.
Boston M&A market in 2026
Global M&A deal value reached approximately $4.5 trillion in 2025, up 40% year-over-year, driven by 70 megadeals exceeding $10 billion. Boston sits at the center of the US technology and life sciences deal market - one of the highest-value M&A ecosystems outside New York.
Middle-market M&A valuations settled at 9.8x EV/EBITDA in 2025, up from 9.4x in 2024. Q1 2025 middle-market volume rose 10.3% year-over-year as buyers regained confidence after significant pressure throughout 2024.
Boston's strength is in life sciences, health technology, enterprise software, defense tech, and business services. The PE firm ecosystem here - General Atlantic, Summit Partners, TA Associates, Warburg Pincus - creates a consistent buyer market for founder exits.
Set up an Ellty data room before your first advisor conversation. Boston buyers check financial documentation, IP ownership, and customer concentration before sending an LOI.
What separates Boston M&A advisors
Boston M&A advisors operate inside one of the world's most active biotech and life sciences deal ecosystems. Advisors with live relationships inside Summit Partners, TA Associates, and General Atlantic see buy-side deal flow before it hits the market.
Capstone Partners is the most active middle-market M&A advisor in Boston, with 175+ professionals across 12 industry groups. They acquired TM Capital in December 2025, adding to one of the most established boutique deal teams in the Northeast. Consilium Partners, founded in 2000, has completed 250+ transactions totaling more than $15 billion in value.
Boston deals in life sciences and biotech require advisors who understand regulatory timelines, IP licensing structures, and how FDA milestones affect buyer valuations. A general business broker won't know how to structure diligence for a biotech platform.
| Advisor | Deal Type | Deal Size | Sector Focus | Website | |
|---|---|---|---|---|---|
| Capstone Partners | Capstone Partners | Both | $25M-$500M | Technology, healthcare, industrials, consumer, business services, A&D | capstonepartners.com |
| Consilium Partners | Consilium Partners | Both | $15M-$100M | Highly engineered products, industrial technology, business services, healthcare services | cpboston.com |
| Bowen Advisors | Bowen Advisors | Both | $10M-$250M | Cloud, cybersecurity, defense tech, healthcare IT, sustainability tech | boweninc.com |
| Houlihan Lokey | Houlihan Lokey | Both | $100M-$5B+ | Technology, healthcare, life sciences, industrials, business services | hl.com |
| William Blair | William Blair | Both | $50M-$2B+ | Technology, healthcare services, health IT, life sciences, medtech | williamblair.com |
| Harris Williams | Harris Williams | Both | $50M-$2B+ | Healthcare & life sciences, technology, business services, industrials | harriswilliams.com |
| Lincoln International | Lincoln International | Both | $50M-$1B+ | Healthcare, technology, business services, industrials, life sciences | lincolninternational.com |
| Piper Sandler | Piper Sandler | Both | $50M-$2B+ | Healthcare, biotech, technology, financial services, government | pipersandler.com |
| Jefferies | Jefferies | Both | $200M-$5B+ | Technology, life sciences, pharma, financial services, industrials | jefferies.com |
| Raymond James | Raymond James | Both | $25M-$1B+ | Technology, healthcare, industrials, financial services, business services | raymondjames.com |
How to verify a Boston M&A advisor's deal record
Ask for a closed deal list with company names, deal sizes, and buyer types from the last 24 months. A credible Boston M&A advisor closes 10+ transactions per year with named buyers.
Check whether the advisor has sold to both Boston-area PE firms and strategic buyers. Selling to TA Associates is structurally different from selling to a corporate strategic. Advisors who've done both know what each buyer demands in diligence.
Ask specifically whether the deal team has sector experience in your sub-market. A Boston life sciences advisor with biotech-specific deal experience delivers materially better buyer lists than a generalist who "covers healthcare."
Use Ellty to share your financial documentation through secure links that track which buyers open which files. Boston buyers who find complete financial records move to LOI faster.
Read the Boston M&A advisors guide for more context on the Boston advisory market before narrowing to a specific firm.
Running an M&A process in Boston?
Organize your financials and IP records before Boston buyers start due diligence.
Start free 14-day trialWhat a Boston M&A deal looks like: 6 stages
Boston M&A sell-side processes run four to eight months. Life sciences and biotech deals often run longer when FDA milestone timing affects buyer valuations.
| Stage | What happens | What you need ready | |
|---|---|---|---|
| Stage 1 | Preparation | Valuation, advisor selection, CIM drafted | 3 years financials, customer list, IP records |
| Stage 2 | Advisor engagement | Engagement letter signed, buyer list built | Engagement letter, NDA template, deal timeline |
| Stage 3 | Marketing | Teaser and CIM sent to strategic and PE buyers | Ellty data room with access staged by NDA tier |
| Stage 4 | LOI | Buyers submit bids, advisor shortlists top three | Updated financials, management deck, product roadmap |
| Stage 5 | Due diligence | Buyer reviews financials, IP, team, and contracts | Full Ellty room: IP, HR, tech docs, customer contracts |
| Stage 6 | Close | Purchase agreement signed, reps and warranties negotiated, funds transfer | Board approvals, wire transfer instructions, escrow setup |
10 Boston M&A advisors in 2026
These firms are active across technology, life sciences, healthcare, industrials, and business services M&A in Boston in 2026.
1. Capstone Partners
Capstone Partners is the most active middle-market M&A advisor in Boston, with 175+ professionals across 12 industry groups. The firm is headquartered in Boston and is a subsidiary of Huntington Bancshares. In December 2025, Capstone Partners acquired TM Capital, adding to one of the most established boutique deal teams in the Northeast. In 2025, Capstone published market data showing Q1 2025 middle-market volume rose 10.3% year-over-year.
Recent Deals: Closed the acquisition of TM Capital (December 2025), expanding the firm's Boston middle-market deal capabilities. Publishes quarterly middle-market M&A valuations data tracking deal activity across all sectors.
LinkedIn: Capstone Partners on LinkedIn
Sector Focus: Technology, healthcare, industrials, consumer, business services, aerospace, defense
Deal Type: Both
Deal Size: $25M-$500M
Location: Boston, MA (headquarters, national network)
Website: capstonepartners.com
2. Consilium Partners
Consilium Partners is a Boston-based investment bank founded in 2000 with more than 250 completed transactions totaling over $15 billion in value. They focus on sell-side M&A advisory for lower-middle market companies in highly engineered products, industrial technology, business services, and healthcare services. Their deal team's depth in niche manufacturing and industrial tech gives Boston-area founders specialized buyer network access.
Recent Deals: Active in industrials, technology, and business services M&A through 2025-2026. Last advised Premier Fence on a 2025 transaction. Completed 250+ lifetime transactions exceeding $15B in total value.
LinkedIn: Consilium Partners on LinkedIn
Sector Focus: Highly engineered products, industrial technology, business services, healthcare services
Deal Type: Both
Deal Size: $15M-$100M
Location: Boston, MA (headquarters)
Website: cpboston.com
3. Bowen Advisors
Bowen Advisors is a Boston-based growth tech investment bank founded in 2002, focused exclusively on technology M&A advisory and private capital for cloud, cybersecurity, defense tech, healthcare IT, and sustainability sectors. They have completed 28 M&A deals through April 2026, with the most recent advising VISO TRUST on a 2026 deal. Bowen's tech-only focus gives Boston software and SaaS founders access to a buyer network built around technology acquirers.
Recent Deals: Advised VISO TRUST on a transaction (2026). Active in cloud, cybersecurity, and defense tech M&A advisory through 2025-2026 with 28+ closed M&A deals.
LinkedIn: Bowen Advisors on LinkedIn
Sector Focus: Cloud, cybersecurity, defense tech, healthcare IT, sustainability, industrial technology
Deal Type: Both
Deal Size: $10M-$250M
Location: Boston, MA (headquarters, national coverage)
Website: boweninc.com
4. Houlihan Lokey
Houlihan Lokey is the No. 1 global M&A advisor by deal volume for transactions under $1B and maintains an active Boston presence covering technology, healthcare, life sciences, and industrials. Their 150+ technology sector professionals and 30+ healthcare officers give Boston-area founders access to a buyer network that most boutiques can't match. Houlihan Lokey's 2025 healthcare group achieved its most successful year in firm history.
Recent Deals: Advised HighFive Healthcare on a $100M growth equity placement from Norwest Venture Partners. Active in technology and healthcare M&A advisory through 2025-2026 as the world's No. 1 M&A advisor.
LinkedIn: Houlihan Lokey on LinkedIn
Sector Focus: Technology, healthcare, life sciences, industrials, business services
Deal Type: Both
Deal Size: $100M-$5B+
Location: Boston, MA (office, global network)
Website: hl.com
5. William Blair
William Blair completed 17 signed or closed healthcare technology advisory deals in 2025 and runs one of the most active mid-market healthcare and technology M&A practices in the US. Their Boston-area team covers healthcare services, health IT, medtech, and life sciences, with strong PE and strategic buyer relationships across the Northeast. William Blair advised Avalon Healthcare Solutions on its November 2025 recapitalization by WindRose Health Investors.
Recent Deals: Advised Avalon Healthcare Solutions on majority recapitalization by WindRose Health Investors (November 2025). Advised KKR on recapitalization of DentalXChange (2025). Completed 17 healthcare technology M&A deals in 2025.
LinkedIn: William Blair on LinkedIn
Sector Focus: Healthcare services, health IT, medical technology, life sciences, pharma outsourcing
Deal Type: Both
Deal Size: $50M-$2B+
Location: Boston, MA (office, national network)
Website: williamblair.com
Boston M&A data room
Organize your IP records and financials before Boston PE buyers start due diligence.
Start free 14-day trial6. Harris Williams
Harris Williams runs dedicated sector teams covering healthcare and life sciences, technology, business services, and industrials - the four most active M&A categories in Boston. Their PE firm relationships give Boston founders access to a buyer network that spans every major middle-market PE shop in the Northeast. Harris Williams publishes quarterly market reports tracking deal activity across all sectors.
Recent Deals: Active in healthcare & life sciences, technology, and business services M&A through 2025-2026 with quarterly sector market reports and West Coast and Northeast coverage.
LinkedIn: Harris Williams on LinkedIn
Sector Focus: Healthcare & life sciences, technology, business services, industrials, consumer
Deal Type: Both
Deal Size: $50M-$2B+
Location: Boston, MA (East Coast coverage, national network)
Website: harriswilliams.com
7. Lincoln International
Lincoln International has more than 30 dedicated healthcare officers and completed 45+ healthcare transactions in an 18-month period through 2025. Their global network gives Boston life sciences and healthcare founders cross-border buyer access to European and Asian strategic acquirers. Lincoln's recent team expansion includes eight Managing Director hires in anticipation of accelerated 2025-2026 deal flow.
Recent Deals: Completed 45+ healthcare transactions in the 18 months through 2025. Hired 8 Managing Directors across sector teams in preparation for 2025-2026 deal volume increase.
LinkedIn: Lincoln International on LinkedIn
Sector Focus: Healthcare, life sciences, technology, business services, industrials
Deal Type: Both
Deal Size: $50M-$1B+
Location: Boston, MA (East Coast coverage, Chicago headquarters)
Website: lincolninternational.com
8. Piper Sandler
Piper Sandler runs an active Boston healthcare and biotech practice, with sector coverage that extends across pharma, medical devices, health IT, and financial services. Their research-backed advisory approach gives Boston healthcare and tech founders real-time buyer sentiment data before going to market. Piper Sandler's biotech coverage is one of the most active in the Northeast.
Recent Deals: Active in healthcare, biotech, and technology M&A advisory through 2025-2026 with dedicated sector teams and Boston market coverage.
LinkedIn: Piper Sandler on LinkedIn
Sector Focus: Healthcare, biotech, pharma, medical devices, technology, financial services
Deal Type: Both
Deal Size: $50M-$2B+
Location: Boston, MA (East Coast office, national network)
Website: pipersandler.com
9. Jefferies
Jefferies provides global buyer access for Boston life sciences, pharma, and technology founders who need international strategic buyer coverage. Their large Boston-area deal team covers pharma, biotech, medical devices, and technology with cross-border deal capability. Jefferies is the right firm for Boston founders where international strategic buyers are part of the buyer pool.
Recent Deals: Active in technology, life sciences, pharma, and financial services M&A through 2025-2026 with global buyer access and East Coast office coverage.
LinkedIn: Jefferies on LinkedIn
Sector Focus: Technology, life sciences, pharma, biotech, medical devices, financial services
Deal Type: Both
Deal Size: $200M-$5B+
Location: Boston, MA (East Coast office, global network)
Website: jefferies.com
10. Raymond James
Raymond James covers technology, healthcare, industrials, and business services in the Boston market with a research-informed advisory approach that gives founders buyer market visibility before going to market. Their Northeast office covers mid-market founder exits and PE-backed platform deals from $25M to $1B. Raymond James pairs M&A advisory with equity research coverage across all key Boston sectors.
Recent Deals: Active in technology, healthcare, and industrials M&A through 2025-2026 with East Coast coverage and a dedicated Boston market presence.
LinkedIn: Raymond James on LinkedIn
Sector Focus: Technology, healthcare, industrials, financial services, business services
Deal Type: Both
Deal Size: $25M-$1B+
Location: Boston, MA (East Coast office, national network)
Website: raymondjames.com
How to choose between a Boston boutique and a large bank
Boston boutiques like Consilium and Capstone offer senior banker attention on every deal. Large banks like Houlihan Lokey and Jefferies offer deeper buyer network access and more global buyer reach for transactions above $100M.
For deals under $50M, a dedicated Boston boutique with sector-specific experience usually outperforms a large bank with a junior team assigned to your deal. For deals above $200M, the large bank's buyer network and brand often justify the tradeoff.
Ask which senior banker will run your deal. At large banks, the Managing Director who pitches the deal often passes day-to-day execution to an associate. Ask this question directly and get the answer in your engagement letter.
Read the investment banking guide to understand what advisors are actually paid to do - and what questions to ask before signing an engagement letter.
How Boston's biotech ecosystem affects M&A
Boston has more active biotech M&A than any US city outside of San Francisco. Kendall Square alone has more biotech M&A activity per square mile than most entire US metros.
FDA milestone timing is a critical variable in biotech M&A valuations. Deals where a Phase 3 readout is 6-12 months away get priced differently than deals where the milestone is 24+ months out. Your advisor needs to know how to time a process around those milestones.
Strategic acquirers in Boston biotech - Sanofi, AstraZeneca, Takeda - all have active BD teams looking for mid-stage programs. Your advisor needs to have current relationships with those BD teams, not just names in a database.
Use Ellty's startup resources to organize your IP and pipeline documentation before life sciences buyers review your data room.
How Ellty helps you run a Boston M&A process
Once you have your advisor, organize your financials and IP. Boston buyers start diligence with financial documentation and IP ownership records.
- 1.Upload financials, contracts, and IP recordsLoad your financial statements and IP documentation before buyer outreach.
- 2.Stage access by NDA tier and buyer typeControl which buyers see your technical IP and trade secrets.
- 3.Track which buyers review which documentsSee which PE firms and strategics review your financial records in real time.
Common questions about Boston M&A advisors
- Capstone Partners is the most active middle-market M&A advisor in Boston, with 175+ professionals across 12 industry groups. They acquired TM Capital in December 2025 to expand their Northeast deal capabilities.
- Expect four to eight months for most deals. Life sciences and biotech deals with FDA milestone timing considerations often run longer, sometimes nine to twelve months.
- For deals under $50M, a sector-specialist Boston boutique usually delivers better outcomes. For deals above $200M where global buyer access matters, a large bank's buyer network and brand often justify the tradeoff.
- FDA milestone timing affects valuations directly. You need an advisor who understands how to time a process around clinical readout milestones and who has live BD team relationships at major pharma strategic acquirers.
- Expect 3-5% for deals under $25M and 1-3% for deals above $100M, with minimum engagement fees common for lower-middle market transactions.
- Before your first advisor meeting. Load your three years of financial statements, IP ownership records, and customer contracts so advisors can assess your deal readiness before quoting a valuation range.
